Intervention Sequence: DCAB for Healthy Subjects

"As Intervention Sequence: ADBC is a Phase 1 trial, with limited clinical data for safety and effectiveness, it has been assigned an initial score of one."

"Affirmative. Clinicaltrials.gov confirms that this study, which was initially posted on March 1st 2023, is currently recruiting candidates. In total, 64 participants are required from a single trial site."

"This clinical trial is seeking individuals aged between 18 and 55 years old. For those below the age of consent, there are 48 trials available to them and 366 for seniors above 65."

"That is correct. Clinicaltrials.gov offers confirmation that the trial, which was initially listed on January 3rd 2023, is presently recruiting individuals for enrollment. 64 participants are needed from 1 medical centre."

"This clinical trial is currently recruiting 64 volunteers, aged 18 to 55, with the health status of a healthy individual. They must also fulfill additional requirements such as passing physical examination and medical history reviews prior to enrollment. Additionally, female participants need to have negative Beta-HCG results while male candidates should abstain from donating sperm for 6 months following their last dose in this study. All participants are expected sign an Informed Consent Form (ICF) that they understand the purpose and procedure during the study period prior to joining it."

"The primary objective of this medical trial, to be assessed over a 168 hour period beginning with pre-dose measurements, is determining the Area Under the Plasma Concentration-time Curve from Time 0 to 72 Hours (h) (AUC[0-72h]) for Lazertinib in Interventions A, B and C. Other outcomes include further analysis of AUC(0-72h) related to interventions A and D; Number of Participants With Adverse Events (AEs); and Number of Participants With Serious Adverse Events (SAEs)."